Browse by Title

• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• #

• T
• Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: A Multi-Institutional Experience (M3)
  Favorite
  James Sun, MD – Moffitt Cancer Center ### 915799###Oral Abstract Presenter M3
• The Hidden Length of Stay following Cytoreductive Surgery/HIPEC: Risk Factors for Unplanned 90-Day Readmission (PM2)
  Favorite
  Robert J. Torphy, MD – University of Colorado ### 915800###Oral Abstract Presenter PM2
• Travel Distance and the Impact on Post-Surgical Outcomes and Overall Survival after CRS/HIPEC. A Study from the US HIPEC Collaborative (PM3)
  Favorite
  Bernardo M. Pessoa, MD – Johns Hopkins University ### 926139###Oral Abstract Presenter PM3
• Treatment Variation and Long-Term Outcomes of Appendiceal Neoplasms (PM13)
  Favorite
  Christopher Scally, MD, MS – University of Texas MD Anderson Cancer Center ### 915792###Oral Abstract Presenter PM13
• Two cases with panel discussion
  Favorite
  Alexandra Gangi, MD – Cedars Sinai Medical Center ### 915762###Moderator @@@ Sepideh Gholami, MD – University of California Davis Health ### 915764###Moderator